Pantoprazole, analogs and substitutes. Price, reviews

Pantoprazole is an antiulcer drug that belongs to the pharmacological group of proton pump inhibitors. This product is available in the form of white tablets covered with a protective layer of enteric film. The active substance of this medication is the chemical compound of pantoprazole sodium sesquihydrate at a dosage of 20 and 40 mg.

The drug Pantoprazole has the pharmacological property of blocking the production of hydrochloric acid. Exactly the same effect has drugs that are its analogues and substitutes. Pantoprazole is used to treat gastric ulcer and duodenal ulcers. It can be used as the main therapeutic agent for erosive gastritis.

Domestic and imported analogues of the product

Pantoprazole is a drug produced by the Russian pharmaceutical company Atoll LLC. On the market for antiulcer drugs, there is a wide selection of analogues and substitutes for this drug, which have identical therapeutic properties.

Zipantola

Pantoprazole and Zipantol are drugs that are complete analogues.

The following pharmacological similarities of these medicines are distinguished:

• both drugs contain the same active ingredient in the form of pantoprazole with a dosage of 20 and 40 mg;
• the form of release of drugs is tablets covered with a layer of a special film with enteric properties;
• Pantoprazole and Zipantol belong to the same pharmacological group of proton pump inhibitors;
• both drugs have pronounced anti-ulcer properties, which are manifested in blocking the final stage of the synthesis of hydrochloric acid;
• the drugs Zipantol and Pantoprazole show their effect only under conditions of stomach acidity, which is not exceeds pH 3 (at high acidity levels, these medicines lose their therapeutic efficiency);
• these drugs are used as the main or auxiliary agent in the treatment of gastric ulcers, and also the walls of the duodenum, regardless of the reasons that caused the pathological state of the digestive systems;
• Zipantol and Pantoprazole have the same property of enhancing the natural sensitivity of the bacterial microorganism Helicobacter pylori to antibiotics (for example, if a person is undergoing complex therapy for peptic ulcer disease using antimicrobial agents);
• both drugs have a beneficial effect on the state of motility of the gastrointestinal tract without disturbing its physiological rhythm;
• Zipantol and Pantoprazole block the synthesis of hydrochloric acid only for a short period of time, and restoration of the previous composition of gastric juice occurs 3-4 days after the termination of therapy by these means;
• these medicines are characterized by a very rapid absorption of their active substance into the walls of the gastrointestinal tract with further penetration into the general blood flow;
• the bioavailability of the constituent components of the Zipantol and Pantoprazole tablets is at the level of 77%, which is considered an extremely low indicator;
• both drugs equally interact with the digestive tract, regardless of the patient's meal schedule, his diet and diet;
• the maximum concentration of the active substance of these medicines reaches a level of 2 to 3 μg per 1 ml of blood 2.5 hours after taking a standard therapeutic dosage (this indicator remains unchanged, despite the further frequency of use drugs).

Pantoprazole, analogs and substitutes for which are sold in most city pharmacies, is characterized by a convenient dosage form. The patient who is assigned to take this medication can purchase tablets with a mass fraction of the active substance of 20 or 40 mg.

Due to the fact that the drugs Pantoprazole and Zipantol are complete analogues, there is a minimum number of differences between them, which consist in the following characteristics:

• Zipantola is a foreign analogue of the drug Pantoprazole, which is produced by the Croatian pharmaceutical company Pliva Khrvatska;
• Zipantol tablets are characterized by a rich yellow tint, and Pantoprazole has a white shell;
• a distinctive feature of the preparation analogue Zipantol is that on one side of the tablets there is a green inscription "RA 783".

In case of therapeutic necessity, the drug Zipantol can completely replace the drug Pantoprazole. The decision to use an analogue is made by a gastroenterologist who treats a patient with pathologies of the digestive system.

Controlok

Controlok is a drug that is a foreign analogue of Pantoprazole.

These medicines are characterized by the following pharmacological similarities:

• Controloc and Pantoprazole are antiulcer drugs, the intake of which contributes to a faster recovery of damaged parts of the stomach, as well as the duodenum;
• both medicines belong to the same pharmacological group of proton pump inhibitors;
• medicines of these types are produced in the form of tablets covered with a layer of an enteric film;
• the drugs Controloc and Pantoprazole have a similar therapeutic effect, which consists in a decrease in the active synthesis of hydrochloric acid, which automatically leads to a decrease in the concentration of gastric juice;
• both medicines accelerate the process of tissue regeneration of the damaged organs of the gastrointestinal tract by reducing their irritability with an increased level of acidity;
• the drugs Controlok and Pantoprazole enhance the pharmacological properties of antimicrobial drugs, the constituent components of which are effective against the bacteria Helicobacter pylori;
• medicines of this type have similar indicators of pharmacokinetic activity after their single and repeated administration;
• metabolic degradation of Controloc and Pantoprazole tablets occurs in the liver tissues with the formation of the final product desmethylpantoprazole (this substance is found in the urine and blood serum of patients receiving systemic therapy with these drugs);
• these drugs are characterized by a similar level of binding to blood plasma proteins, which is 0.15 l per 1 kg;
• the half-life of the drugs Controlok and Pantoprazole is 1 hour with a stable clearance of 0.1 l in 60 minutes. based on 1 kg of the patient's body weight;
• both antiulcer drugs, after metabolic degradation in the liver tissues, are excreted from the body along with urine and feces (about 80% of these drugs are utilized as part of urine, and another 20% is removed through intestines);
• the active substances of the medicines Controlok and Pantoprazole do not accumulate in the tissues of internal organs, and also do not require selection of a special dosage regimen for patients with renal insufficiency (including patients on hemodialysis);
• both drugs are allowed to be taken with the simultaneous use of food, the diet does not affect the absorption of the active components of these tablets;
• in patients who have a concomitant disease of the body in the form of liver cirrhosis, the drugs Pantoprazole and Controls cause higher values ​​of the maximum concentration of the active substance in the serum blood.

Pantoprazole (analogs and substitutes for this drug are dispensed by prescription from the attending gastroenterologist) is a systemic antiulcer. This medication has the following differences with a proton pump inhibitor

Controlok:

• the layer of a protective enteric film in the drug Controlok has a rich yellow tint, and Pantoprazole tablets are completely white;
• antiulcer drug Controlok is produced by a foreign enterprise of the pharmaceutical industry - "Takeda" with headquarters in Japan;
• the packaging of the drug Controlok is carried out in polymer blisters of no more than 7 or 14 tablets in each, and Pantoprazole is placed in cassettes of 14, 35, 30 and 50 tablets, and packaging in the form of polymer cans is also used.

Due to the fact that the drugs Controlok and Pantoprazole are complete analogues the gastroenterologist treating the patient decides to use only one of the the specified medications.

Crossacid

Crosacid is a tablet preparation that is used to treat pathological conditions of the gastrointestinal tract caused by ulcerative lesions of their mucous membranes. The following pharmacological similarities exist between Pantoprazole and its full analogue Crosacid:

• both medicines belong to a single pharmacological group of proton pump inhibitors;
• Crosacid and Pantoprazole have a similar mechanism of therapeutic action, which is manifested by a decrease in the functional activity of the gastric glands responsible for the synthesis of hydrochloric acid;
• the active substance of these medicines shows an independent antimicrobial efficacy in against the pathogenic microorganism Helicobacter pylori, which causes signs of gastritis and ulcerative illness;
• Crosacid and Pantoprazole have the same pharmacokinetic properties;
• the metabolic transformation of the active substance of these drugs occurs in the liver tissues with their further excretion through the kidneys and intestines while maintaining a stable ratio of 80 to 20% of biochemical products decay;
• Crosacid and Pantoprazole exhibit similar therapeutic activity during the treatment of peptic ulcer disease caused by chronic stress, prolonged use of non-steroidal anti-inflammatory drugs, as well as complications of concomitant pathologies of the gastrointestinal tract;
• the dosage of both drugs is selected only on an individual basis by a gastroenterologist after a comprehensive examination of the patient's digestive system;
• antiulcer drugs Crosacid and Pantoprazole can cause side effects that disrupt processes hematopoiesis (for example, pathological conditions of the vascular system in the form of thrombocytopenia, agranulocytosis, leukopenia);
• both medications are contraindicated in patients who are diagnosed with dyspeptic phenomena of a neurotic nature of origin, as well as oncological diseases of the digestive tract;
• the drugs Crosacid and Pantoprazole are not prescribed for women who are pregnant, and are also breastfeeding a newborn baby;
• drugs of this type similarly affect patients with severe hepatic insufficiency, reducing the functional activity of this organ;
• medicines analogues Crosacid and Pantoprazole, which are taken during a continuous therapeutic course with a duration of more than 12 months, can cause fractures of the spine, femur, and wrist (this negative property of drugs extends to elderly patients age).

Despite a large number of similar pharmacological characteristics, the drugs Crosacid and Pantoprazole have the following differences:

• Crosacid is produced with a maximum therapeutic dosage of 20 mg, and Pantoprazole is sold in the form of tablets with an active substance concentration of 20 and 40 mg;
• the Indian pharmaceutical company "Micro Labs" is engaged in the production of the drug Krosacid, and the drug Pantoprazole is a domestic drug;
• packing of Krosacid is carried out not only in polymer blisters, but also in plastic cans of 100 tablets.

Pantoprazole (analogues and substitutes of the drug exhibit exactly the same therapeutic efficacy) is an antiulcer drug that does not have a cumulative principle of action. 3-4 days after stopping its intake in a person, the previous activity of the glands of the stomach for the synthesis of hydrochloric acid is restored.

Nolpaza

Nolpaza is an analogue of the drug Pantoprazole, which is used to treat inflammatory and erosive pathologies of the digestive system.

These medicines are characterized by the following pharmacological similarities:

• belong to a single therapeutic category of drugs, proton pump inhibitors;
• both drugs have a pronounced antiulcer effect, contributing to faster healing of wound sites on the gastric mucosa, as well as the duodenum;
• these medicines contain a similar active substance in the form of pantoprazole with a concentration of 40 mg in 1 tablet;
• Nolpaza and Pantoprazole are characterized by the same principle of therapeutic action, which is expressed in the suppression of physiological the functions of the gastric glands responsible for the synthesis of hydrochloric acid (the pH of the gastric juice of the patient taking these drugs drops to level 3 units);
• antiulcer drugs of these types are equally effective in the treatment of pathological conditions of the gastrointestinal tract caused by the pathogenic activity of the bacterial microorganism Helicobacter pylori;
• Nolpaza and Pantoprazole have a similar effect on the gastric mucosa of patients with symptoms erosive gastritis (in this case, medications prevent the exacerbation of the disease to the level of ulcerative defeat);
• the dosage regimen and the timing of therapy with these drugs are selected exclusively by a gastroenterologist, taking into account the diagnosis made, the general condition of the patient's digestive system and the dynamics to restore normal integrity gastrointestinal mucosa;
• antiulcer drugs Nolpaza and Pantoprazole have identical side effects, which are the fact that these medicines provoke the growth of polyps in the structure of the fundic glandular tissue stomach;
• drugs of this type can temporarily change the sensitivity of the patient's taste buds, lead to sleep disturbances, cause anxiety and headache attacks;
• Nolpaza and Pantoprazole have similar negative drug interactions with Atazanavir, Nelfinavir, as well as other HIV protease inhibitors (medicines of these categories are contraindicated for simultaneous reception);
• both antiulcer drugs are not used to treat patients who have an individual intolerance to the active substance of the tablets - pantoprazole, regardless of its concentration in the composition 1 pills;
• Nolpaza and Pantoprazole are equally contraindicated for use in women who are in a state of pregnancy, breastfeeding a newborn baby;
• the dosage of these medicines cannot exceed 40 mg per day for patients who have functional disorders in the work of the kidneys (similar recommendations apply to the treatment of elderly patients, since they have an increased risk of bone fractures fabrics);
• a prerequisite for the use of Nolpaza and Pantoprazole tablets is a preliminary examination of the gastrointestinal tract of the patient with complete exclusion of tumor neoplasms in the tissues of the digestive systems;
• both drugs have the pharmacological property of creating an additional load on the liver tissue, therefore, patients with chronic diseases of this organ should regularly donate venous blood for its study on the level of hepatic enzymes;
• Nolpaza and Pantoprazole can cause dizziness, reduce the speed of psychomotor reactions, and also impair concentration;
• antiulcer drugs of these types violate the quality of absorption of drugs, the absorption of which depends on the level of acidity of gastric juice (for example, the simultaneous administration of Nolpaza or Pantoprazole with Ketoconazole, Erlotinib, Posaconazole will lead to a decrease in therapeutic efficacy the latter).

Pantoprazole (analogues and substitutes for this drug are produced by foreign pharmaceutical companies) is a drug that has the following differences from the antiulcer drug Nolpaz:

• Pantoprazole tablets are characterized by a completely white color, and the Nolpaza shell has a yellowish brown tint;
• Pantoprazole is produced by a Russian pharmaceutical company, and Nolpaza is an imported analogue produced by the Slovenian enterprise KRKA;
• Nolpaza is presented only in a dosage of 40 mg with packaging of the drug in polymer blisters of 14 tablets. in each, and Pantoprazole is also produced at a concentration of 20 mg (this form is convenient for patients who need therapy with lower doses of antiulcer drugs).

Nolpaza and Pantoprazole are interchangeable medicines that are equally effective in the treatment of inflammatory and ulcerative diseases of the digestive system.

Prices

The average cost of the antiulcer drug Pantoprazole is 94 rubles. for 28 tab. with an active substance concentration of 20 mg. The table below lists the main analogues of this drug, as well as their prices in retail pharmacy chains.

Name of the medication	average cost
Zipantola	from 620 to 690 rubles.
Controlok	from 195 to 307 rubles.
Crossacid	from 115 to 449 rubles.
Nolpaza	from 142 to 365 rubles

Pantoprazole is an effective drug belonging to the group of proton pump inhibitors. This drug is used for the complex treatment of peptic ulcer disease that affects the stomach and duodenal mucosa.

Pantoprazole is produced by a domestic pharmaceutical company, which makes it more affordable from a material point of view. On the pharmacological market of the Russian Federation, there are other analogues and substitutes for this medication, which have exactly the same therapeutic properties. Reception of the drug Pantoprazole is carried out throughout the continuous course. Stopping further use of this medication returns the level of gastric acidity to its previous level.

Video about Pantoprazole analogues

Malysheva on proton pump inhibitors: